BioStem Technologies to Present Expanded Product Portfolio and Clinical Evidence at Major Wound Care Symposium

BioStem Technologies announced its participation in the Symposium on Advanced Wound Care Spring meeting in Charlotte, NC, from April 8-12, 2026. The company will highlight its recently introduced Neox Product line, which expands its capabilities across multiple tissue formats and provides physicians with differentiated options depending on clinical needs, handling preferences, and site of care requirements. Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that the expanded portfolio offers the most comprehensive suite of placental and umbilical cord tissue solutions, backed extensively by both randomized clinical trials and real-world evidence.

During the symposium, BioStem will host an Innovation Theater Lunch Symposium titled "A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence" on Thursday, April 9th, from 12:15 p.m. to 1:45 p.m. in Room 207C. The luncheon will feature presentations by Dr. Wendy Weston, PhD, CTBS, William Marston, MD, and Herbert Slade, MD, and will include discussion of several key topics. These include an introduction to the newly expanded BioStem Technologies product portfolio, the science behind its innovative suite of birth tissue products, and the recently published results of a randomized controlled trial on diabetic foot ulcers. The session will also provide practical guidance on how to incorporate these therapies into clinical practice and conclude with a live question-and-answer session.

BioStem will also present a new scientific poster presentation, which will be available for viewing in Exhibit Hall 1C with poster number LR-020. The company's participation demonstrates its continued investment in clinical research and medical education as it works to expand access to advanced healing technologies across a wide range of care settings. The symposium represents one of the premier gatherings for wound care professionals, clinicians, and researchers, making it a significant platform for showcasing advancements in regenerative medicine.

The company's expanded portfolio now includes the Neox product line alongside its existing brands, creating what company leadership describes as the most comprehensive suite of placental and umbilical cord tissue solutions available. This expansion is particularly important because it provides clinicians with more options tailored to specific patient needs and clinical scenarios. The emphasis on both randomized clinical trials and real-world evidence strengthens the scientific foundation for these therapies, addressing a critical need in wound care for treatments supported by robust clinical data.

BioStem's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks, established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. The company's portfolio of quality brands includes its Neox, Clarix, VENDAJE and American Amnion product lines, all derived from perinatal tissue using proprietary processing technologies designed to optimize preservation of natural tissue properties. More information about the company is available at https://www.biostemtechnologies.com.